RxDoctor Payments Data

Marcus Feldpausch, PA

Physician Assistant · Ovid, MINPI 1942759295

Payments from drug & device makers

$1,170in general payments, 2019–2025

Across 61 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$269
  • Amgen$230
  • Lilly USA, LLC$133
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$115
  • GSK$88
  • Exact Sciences$62
  • plus $273 from 10 others

What the payments were for

  • Food & beverage$1,170100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,170 in reported general payments places this provider in the 75th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$28,001
Medicare patients
149
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide133$132,508
EliquisApixaban110$84,359
MounjaroTirzepatide54$58,712
JardianceEmpagliflozin50$57,036
Repatha SureclickEvolocumab46$39,250
OzempicSemaglutide40$36,886
XareltoRivaroxaban41$34,398
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$31,849
JanuviaSitagliptin Phosphate17$19,047
InvokanaCanagliflozin18$15,024
Lantus SolostarInsulin Glargine,hum.Rec.Anlog90$13,592
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$10,988
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$10,662
Spiriva RespimatTiotropium Bromide13$9,676
TrintellixVortioxetine Hydrobromide14$9,434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$133$191,221187 claims
PfizerEliquis$20$84,359110 claims
GSKTrelegy Ellipta, Anoro Ellipta$88$42,51172 claims
Novo NordiskOzempic$269$36,88640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Ovid

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →